Target type: biologicalprocess
The establishment, maintenance and elaboration of the left/right axis. The left/right axis is defined by a line that runs orthogonal to both the anterior/posterior and dorsal/ventral axes. Each side is defined from the viewpoint of the organism rather of the observer (as per anatomical axes). [GOC:dph, GOC:gvg, GOC:mah]
The establishment of the left-right (L/R) axis is a fundamental process in animal development, defining the body plan and ensuring the correct placement of organs. This complex process involves a series of molecular and cellular events, beginning with the initial asymmetry observed in the early embryo.
**1. Early Asymmetry:**
The first sign of L/R asymmetry often appears in the form of cilia, tiny hair-like structures on the surface of cells. In many animals, a group of specialized cilia, known as nodal cilia, are located in the node (a region of the developing embryo) and beat in a leftward direction. This coordinated movement generates a leftward flow of fluid, creating a localized asymmetry in the concentration of signaling molecules.
**2. Nodal Signaling and Lefty:**
The leftward flow of fluid activates downstream signaling pathways, primarily involving the Nodal signaling pathway. Nodal is a secreted signaling molecule that activates downstream transcription factors, including Pitx2, which plays a crucial role in specifying left-sided identity. Importantly, the right side of the node expresses a molecule called Lefty, which acts as an antagonist of Nodal, preventing its diffusion to the right side.
**3. Establishing Left and Right Identities:**
The asymmetric distribution of Nodal and Lefty leads to differential gene expression on the left and right sides of the embryo. This results in the establishment of distinct left and right identities, with specific genes and proteins being expressed on each side. For instance, the expression of Pitx2 on the left side is essential for the development of left-sided organs, such as the heart and stomach.
**4. Organ Asymmetry and Function:**
The establishment of the L/R axis is crucial for proper organ development and function. Many organs, including the heart, lungs, liver, and gut, exhibit distinct left and right asymmetry. For example, the heart is positioned on the left side of the body, while the liver is located on the right side. This asymmetry is essential for proper organ function, as each side of the body performs specific tasks.
**5. Conservation and Evolution:**
The L/R axis specification pathway is highly conserved across different animal species, suggesting its fundamental importance in development. However, variations in the mechanisms and genes involved in this process have been observed, reflecting the evolutionary adaptations of different animal groups.
**6. Defects in Axis Specification:**
Disruptions in the L/R axis specification pathway can lead to serious developmental defects, such as situs inversus (a complete reversal of organ positions), heterotaxia (a mixture of left and right organ positions), and congenital heart defects. These conditions highlight the importance of proper L/R axis establishment for normal development and function.'
"
Protein | Definition | Taxonomy |
---|---|---|
Smoothened homolog | A protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835] | Homo sapiens (human) |
Neurogenic locus notch homolog protein 1 | A neurogenic locus notch homolog protein 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P46531] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
calotropin | calotropin: structure in first source | cardenolide glycoside | |
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
pd 173955 | PD 173955: inhibits src family-selective tyrosine kinase; structure in first source | aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine | tyrosine kinase inhibitor |
purmorphamine | purmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group. purmorphamine: structure in first source | aromatic ether; morpholines; purines; secondary amino compound | osteogenesis regulator; SMO receptor agonist |
cur 61414 | CUR 61414: inhibits the hedehog signaling pathway; structure in first source | ||
abt 869 | aromatic amine; indazoles; phenylureas | angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | |
lde225 | sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. sonidegib: specific Smoothened/Smo antagonist | aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist |
gdc 0449 | HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity | benzamides; monochlorobenzenes; pyridines; sulfone | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent |
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide | thioureas | ||
ipi-926 | IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first source | piperidines | |
gsk 1363089 | GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source | aromatic ether | |
tak-441 | TAK-441: structure in first source | ||
ly2940680 | |||
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | BGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor. infigratinib: structure in first source | aminopyrimidine; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas | antineoplastic agent; fibroblast growth factor receptor antagonist |
cep-32496 | agerafenib: inhibitor of RAF family kinases; structure in first source | ||
pf-5274857 | 1-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source |